Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Tricoci P, et al. Among authors: widimsky p. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077816 Free article. Clinical Trial.
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Valgimigli M, et al. Among authors: widimsky p. Am J Cardiol. 2014 Sep 1;114(5):665-73. doi: 10.1016/j.amjcard.2014.05.054. Epub 2014 Jun 18. Am J Cardiol. 2014. PMID: 25129064 Clinical Trial.
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.
Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB. Lopes RD, et al. Among authors: widimsky p. Eur Heart J. 2009 Aug;30(16):2019-28. doi: 10.1093/eurheartj/ehp213. Epub 2009 Jun 6. Eur Heart J. 2009. PMID: 19502623 Free PMC article. Clinical Trial.
Intravenous platelet blockade with cangrelor during PCI.
Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators. Bhatt DL, et al. Among authors: widimsky p. N Engl J Med. 2009 Dec 10;361(24):2330-41. doi: 10.1056/NEJMoa0908629. N Engl J Med. 2009. PMID: 19915222 Free article. Clinical Trial.
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights.
van Diepen S, Widimsky P, Lopes RD, White KR, Weaver WD, Van de Werf F, Ardissino D, van't Hof AW, Armstrong PW, Granger CB. van Diepen S, et al. Among authors: widimsky p. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):437-44. doi: 10.1161/CIRCOUTCOMES.112.965160. Epub 2012 May 15. Circ Cardiovasc Qual Outcomes. 2012. PMID: 22589297 Free PMC article. Clinical Trial.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Bhatt DL, et al. Among authors: widimsky p. N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056/NEJMoa1300815. Epub 2013 Mar 10. N Engl J Med. 2013. PMID: 23473369 Free article. Clinical Trial.
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions.
Halim SA, Clare RM, Newby LK, Lokhnygina Y, Schweiger MJ, Hof AW, Hochman JS, James SK, White HD, Widimsky P, Betriu A, Bode C, Giugliano RP, Harrington RA, Zeymer U. Halim SA, et al. Among authors: widimsky p. Int J Cardiol. 2016 Jan 15;203:708-13. doi: 10.1016/j.ijcard.2015.11.036. Epub 2015 Nov 10. Int J Cardiol. 2016. PMID: 26587725 Clinical Trial.
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators. Steg PG, et al. Among authors: widimsky p. N Engl J Med. 2019 Oct 3;381(14):1309-1320. doi: 10.1056/NEJMoa1908077. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475798 Free article. Clinical Trial.
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators; Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P. Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, et al. Among authors: widimsky p. Circulation. 2008 Feb 19;117(7):886-96. doi: 10.1161/CIRCULATIONAHA.107.759167. Epub 2008 Feb 4. Circulation. 2008. PMID: 18250271 Clinical Trial.
478 results